Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.67 USD
-0.15 (-3.93%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.68 +0.01 (0.27%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
AVIR 3.67 -0.15(-3.93%)
Will AVIR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AVIR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AVIR
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy
AVIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade
Other News for AVIR
Atea Pharmaceuticals: Hold Rating Amidst Clinical Trial Setbacks and Future HepC Focus
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
Atea stock drops as COVID-19 therapy fails in late-stage trial
Atea Pharmaceuticals Phase 3 SUNRISE-3 trial did not meet primary endpoint
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir?s Metabolic Activation Pathway